{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-073326","form_type":"8-K","ticker":"BRNS","cik":"0001828185","company_name":"Barinthus Biotherapeutics plc.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.940126+00:00","generated_at":"2026-06-13T20:15:52.397205+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Vaccitech reports positive final Phase 1b/2 HBV002 data; two patients achieve non-detectable HBsAg","bullets":["Two of five patients with baseline HBsAg <100 IU/mL in Group 3 developed non-detectable HBsAg, sustained eight months after last dose.","Group 3 mean HBsAg reduction 0.76 log10 at 2 months (p<0.001) and 0.98 log10 at 8 months (p<0.001).","VTP-300 monotherapy in Group 2 showed 0.7-1.4 log10 declines in three participants; robust T cell response correlated with HBsAg decline.","Phase 2b trial HBV003 >40% enrolled (48/120); interim data expected Q4 2023.","Phase 2a trial with Arbutus (VTP-300 after AB-729) in 40 patients; interim data expected Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-073326","json":"https://secwatch.observer/filing/0001104659-23-073326.json","markdown":"https://secwatch.observer/filing/0001104659-23-073326.md","text":"https://secwatch.observer/filing/0001104659-23-073326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923073326/0001104659-23-073326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1828185/000110465923073326/tm2319306d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T20:15:52.397205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}